title: Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan.
abstract: Mass screening for liver cancer based mainly on abdominal ultrasound was begun in major cities of Hokkaido, Japan, in November 1981, to enable early detection and treatment of hepatocellular carcinoma (HCC). Serum alpha-fetoprotein levels were also measured to minimize false negative studies. Examinees included those who sought liver disease screening as well as high risk individuals: hepatitis B surface antigen carriers and those with a past or current liver disease, history of blood transfusion, family history of liver cancer, and more recently those with positive anti-hepatitis C antibodies. The examination was carried out on each Saturday and Sunday as one round, and by February 1992 48 rounds had been performed. A total of 8090 individuals were investigated, and HCC was detected in 91 with a detection rate of 1.12%. This rate was 1.6% among 5684 individuals who were selected for high risk. Cumulative rates of survival among these patients were 79.0% at 1 year, 43.8% at 3 years, 19.3% at 5 years and 15.4% at 7 years. These survival rates were comparable with those for the patients with HCC diagnosed during follow-up of chronic liver disease and treated at our hospital. The cost for detecting one HCC patient in this programme was 2,660,000 yen (approximately US$25,000), which was less than those for some other types of cancer in a similar setting. Considering the high detection rate in this programme, we feel that similar programmes should be encouraged and supported.
authors.affiliation: Department of Internal Medicine, Hokkaido Kin'ikyo Central Hospital, Sapporo, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Mima
authors.forename: C
authors.initials: C
authors.lastname: Sekiya
authors.forename: H
authors.initials: H
authors.lastname: Kanagawa
authors.forename: H
authors.initials: H
authors.lastname: Kohyama
authors.forename: K
authors.initials: K
authors.lastname: Gotoh
authors.forename: H
authors.initials: H
authors.lastname: Mizuo
authors.forename: M
authors.initials: M
authors.lastname: Ijiri
authors.forename: T
authors.initials: T
authors.lastname: Tanabe
authors.forename: N
authors.initials: N
authors.lastname: Maeda
authors.forename: K
authors.initials: K
authors.lastname: Okuda
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000517:prevention & control*; D003365:Costs and Cost Analysis; D005188:False Negative Reactions; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000517:prevention & control*; D008297:Male; D008403:Mass Screening / Q000191:economics / Q000379:methods*; D008875:Middle Aged; D012307:Risk Factors; D015996:Survival Rate; D014463:Ultrasonography; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D000509:alpha-Fetoproteins